Nam Daleum, Kim Hyejung, Choi Dong-Joo, Bae Yun-Hee, Lee Byoung Dae, Son Ilhong, Seol Wongi
InAm Neuroscience Research Center, Sanbon Medical Center, College of Medicine, Wonkwang University, Gunposi, Gyeonggido, Republic of Korea.
Department of Pharmacology, School of Medicine, Ajou University, Suwonsi, Gyeonggido, Republic of Korea.
Anim Cells Syst (Seoul). 2018 Mar 22;22(2):140-147. doi: 10.1080/19768354.2018.1453545. eCollection 2018.
Parkinson's disease (PD) is the second most common neurodegenerative disease. Although most PD cases are sporadic, 5-10% of them are hereditary and several pathogenic mutations in related genes have been identified. Mutations in were recently identified as a cause of autosomal dominant PD. However, the basic properties of the mutant proteins are not yet known. We examined stability and neurotoxicity, important characteristics of PD pathogenesis-related proteins, of WT TMEM230 and two pathogenic mutants, R78L and PG5ext, in a dopaminergic neuronal cell line. Our study showed that amount of protein expressed in the same vector backbone was R78L > WT > PG5ext. The stabilities of the mutant proteins were similar to each other, but lower than that of the WT. In addition, overexpression of mutants and WT TMEM230 caused similar levels of neurotoxicity upon MPP treatment when compared to the cells transfected with an empty vector. Because the proteins encoded by two PD-causing genes, and , function in vesicle trafficking, we tested whether they interact. LRRK2 neither interacts with, nor phosphorylates TMEM230. We also investigated the levels of several Rab proteins (Rab1A, 5, 7, 8A and 11) involved in vesicle trafficking after TMEM230 overexpression. However, there was no clear difference of any Rab proteins among cells transfected with an empty vector, TMEM230 WT and mutants-expressing cells, suggesting that TMEM230 does not directly regulate these Rab proteins. Thus, these TMEM230 PG5ext and R78L mutant proteins are not distinctly different from the WT proteins except for their stability. LRRK2: Leucine-rich repeat kinase 2; PD: Parkinson's disease; AD: Alzheimer's disease; RT-PCR: reverse transcription-polymerase chain reaction; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; FACS: fluorescence-activated cell sorting; PBS: phosphate buffered saline; FBS: fetal bovine serum; PI: propidium iodide.
帕金森病(PD)是第二常见的神经退行性疾病。虽然大多数帕金森病病例是散发性的,但其中5-10%是遗传性的,并且已经在相关基因中鉴定出几种致病突变。最近发现[此处原文缺失基因名称]中的突变是常染色体显性帕金森病的一个病因。然而,突变蛋白的基本特性尚不清楚。我们在多巴胺能神经元细胞系中研究了野生型(WT)TMEM230以及两个致病突变体R78L和PG5ext的稳定性和神经毒性,这两者都是帕金森病发病机制相关蛋白的重要特征。我们的研究表明,在相同载体骨架中表达的蛋白量为R78L>WT>PG5ext。突变蛋白之间的稳定性相似,但低于野生型。此外,与用空载体转染的细胞相比,突变体和野生型TMEM230的过表达在MPP处理后引起相似水平的神经毒性。由于两个导致帕金森病的基因[此处原文缺失基因名称]和[此处原文缺失基因名称]所编码的蛋白在囊泡运输中起作用,我们测试了它们是否相互作用。富含亮氨酸重复激酶2(LRRK2)既不与TMEM230相互作用,也不使其磷酸化。我们还研究了TMEM230过表达后几种参与囊泡运输的Rab蛋白(Rab1A、5、7、8A和11)的水平。然而,在用空载体转染的细胞、野生型TMEM230转染细胞和表达突变体的细胞之间,任何Rab蛋白都没有明显差异,这表明TMEM230不直接调节这些Rab蛋白。因此,除了稳定性之外,这些TMEM230 PG5ext和R78L突变蛋白与野生型蛋白没有明显差异。LRRK2:富含亮氨酸重复激酶2;PD:帕金森病;AD:阿尔茨海默病;RT-PCR:逆转录-聚合酶链反应;SDS-PAGE:十二烷基硫酸钠-聚丙烯酰胺凝胶电泳;FACS:荧光激活细胞分选;PBS:磷酸盐缓冲盐水;FBS:胎牛血清;PI:碘化丙啶。